NCT04210193View on ClinicalTrials.gov

Is Intralymphatic Allergen Immunotherapy Effective and Safe?

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 25, 2014

Primary Completion Date

December 1, 2019

Study Completion Date

December 1, 2019

Conditions
Allergic Rhinitis Due to Grass Pollen
Interventions
DRUG

ALK Alutard 5-grasses

0.1 mL of 10 000 SQ-U/mL (1000 SQ-U) as an intralymphatic injection

DRUG

ALK Diluent

0.1 mL of ALK Diluent as an intralymphatic injection

Trial Locations (1)

501 82

Allergy Unit, Södra Älvsborgs Hospital, Borås

All Listed Sponsors
lead

Lars Olaf Cardell

OTHER

NCT04210193 - Is Intralymphatic Allergen Immunotherapy Effective and Safe? | Biotech Hunter | Biotech Hunter